Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:7427's Return-on-Tangible-Asset is ranked better than 64.95% of 1415
companies
in the Biotechnology industry
Industry Median: -35.77
vs ROCO:7427: -17.24
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Related Terms
Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
ROCO:7427 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -19.87% mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Return-on-Tangible-Asset of -19.87% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #496 out of 1415 companies in the Biotechnology industry, placing it in the top 35.1%.
Is Great Novel Therapeutics Biotech & Medicals' Return-on-Tangible-Asset too high?
Great Novel Therapeutics Biotech & Medicals' current Return-on-Tangible-Asset is -19.87%. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #496 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #496 out of 1415 companies for Return-on-Tangible-Asset. This puts Great Novel Therapeutics Biotech & Medicals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Return-on-Tangible-Asset is -19.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$26.01, compared to a current price of NT$73.50 — trading 182.6% above its estimated fair value. The current Return-on-Tangible-Asset is -19.87%. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Return-on-Tangible-Asset is -19.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$73.50 is trading 182.6% above its estimated GF Value™ of NT$26.01.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
Return-on-Tangible-Asset: -19.87%
GF Value™: NT$26.01 vs. price of NT$73.50 (182.6% above fair value)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
37GF Score
Get the complete analysis for ROCO:7427
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
